1 min read
Pfizer Announces Starna CAR-T Licensing Deal Worth Up to $2.6 Billion
The exclusive agreement covers development and commercialization of chimeric antigen receptor T-cell therapies.

Pfizer announced Wednesday an exclusive CAR-T licensing deal with Starna Therapeutics valued at up to $2.6 billion, linking the New York-based drugmaker with a China-based RNA medicines company.
The agreement covers development and commercialization of chimeric antigen receptor T-cell therapies, also known as CAR-T therapies.
Starna Therapeutics is based in China. Pfizer is based in New York.